JP6954676B2 - Pku治療のためのフェニルアラニン非含有タンパク質 - Google Patents
Pku治療のためのフェニルアラニン非含有タンパク質 Download PDFInfo
- Publication number
- JP6954676B2 JP6954676B2 JP2019512755A JP2019512755A JP6954676B2 JP 6954676 B2 JP6954676 B2 JP 6954676B2 JP 2019512755 A JP2019512755 A JP 2019512755A JP 2019512755 A JP2019512755 A JP 2019512755A JP 6954676 B2 JP6954676 B2 JP 6954676B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- dietary
- recombinant
- genus
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 193
- 102000004169 proteins and genes Human genes 0.000 title claims description 184
- 201000011252 Phenylketonuria Diseases 0.000 title claims description 75
- 235000018102 proteins Nutrition 0.000 claims description 180
- 102000015781 Dietary Proteins Human genes 0.000 claims description 105
- 108010010256 Dietary Proteins Proteins 0.000 claims description 105
- 235000021245 dietary protein Nutrition 0.000 claims description 105
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 89
- 150000001413 amino acids Chemical group 0.000 claims description 74
- 235000007882 dietary composition Nutrition 0.000 claims description 31
- 244000005700 microbiome Species 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 244000063299 Bacillus subtilis Species 0.000 claims description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 9
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 7
- 241000589516 Pseudomonas Species 0.000 claims description 6
- 241000191940 Staphylococcus Species 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 4
- 241000589236 Gluconobacter Species 0.000 claims description 4
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000194107 Bacillus megaterium Species 0.000 claims description 3
- 241000863012 Caulobacter Species 0.000 claims description 3
- 241000193155 Clostridium botulinum Species 0.000 claims description 3
- 241000186216 Corynebacterium Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000320412 Ogataea angusta Species 0.000 claims description 3
- 241000235648 Pichia Species 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 3
- 241000187747 Streptomyces Species 0.000 claims description 3
- 241000680806 Blastobotrys adeninivorans Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241001138401 Kluyveromyces lactis Species 0.000 claims description 2
- 241000589634 Xanthomonas Species 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 2
- 241000186359 Mycobacterium Species 0.000 claims 2
- 241000194035 Lactococcus lactis Species 0.000 claims 1
- 241000589323 Methylobacterium Species 0.000 claims 1
- 241000232299 Ralstonia Species 0.000 claims 1
- 241000235017 Zygosaccharomyces Species 0.000 claims 1
- 235000005911 diet Nutrition 0.000 description 144
- 230000037213 diet Effects 0.000 description 110
- 235000001014 amino acid Nutrition 0.000 description 71
- 229940024606 amino acid Drugs 0.000 description 71
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 40
- 230000000378 dietary effect Effects 0.000 description 34
- 230000001225 therapeutic effect Effects 0.000 description 34
- 235000016709 nutrition Nutrition 0.000 description 28
- 239000003797 essential amino acid Substances 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 239000000356 contaminant Substances 0.000 description 21
- 235000020776 essential amino acid Nutrition 0.000 description 21
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 20
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 18
- 235000008729 phenylalanine Nutrition 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 125000002435 L-phenylalanyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 235000021004 dietary regimen Nutrition 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 101710194254 General stress protein 16O Proteins 0.000 description 4
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- -1 compound sapropterin dihydrochloride Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- RKSUYBCOVNCALL-NTVURLEBSA-N sapropterin dihydrochloride Chemical compound Cl.Cl.N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 RKSUYBCOVNCALL-NTVURLEBSA-N 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000003367 Hypopigmentation Diseases 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000605114 Pedobacter heparinus Species 0.000 description 3
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002036 drum drying Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000003425 hypopigmentation Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 229940003703 kuvan Drugs 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 229960004617 sapropterin Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000014252 Mild phenylketonuria Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 241000519590 Pseudoalteromonas Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 102000021178 chitin binding proteins Human genes 0.000 description 2
- 108091011157 chitin binding proteins Proteins 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000012438 extruded product Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000026770 mild hyperphenylalaninemia Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 101150036331 pah gene Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000012015 potatoes Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 229960004209 sapropterin dihydrochloride Drugs 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 235000012773 waffles Nutrition 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000029751 Amino acid metabolism disease Diseases 0.000 description 1
- 101000765239 Bacillus subtilis (strain 168) Anthranilate synthase component 1 Proteins 0.000 description 1
- 208000034920 Body Weight Maintenance Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000481 Maternal phenylketonuria Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- KFNNIILCVOLYIR-UHFFFAOYSA-N Propyl formate Chemical group CCCOC=O KFNNIILCVOLYIR-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000004469 amino acid formulation Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000012820 baking ingredients and mixes Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQKDTTWZXHEGAQ-UHFFFAOYSA-N propyl carbonochloridate Chemical compound CCCOC(Cl)=O QQKDTTWZXHEGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000020195 rice milk Nutrition 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 239000008281 solid sol Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/195—Proteins from microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- General Preparation And Processing Of Foods (AREA)
- Soy Sauces And Products Related Thereto (AREA)
Description
別の態様では、本発明は、組換え食餌療法タンパク質又はその食餌療法として十分な部分をコードするベクターを含む組換え微生物に関する。1つの実施形態では、微生物は、エシェリキア属(Escherichia)、クレブシェラ属(Klebsiella)、シュードモナス属(Pseudomonas)、キサントモナス属(Xanthomonas)、バチルス属(Bacillus)、スタフィロコッカス属(Staphylococcus)、サッカロミセス属(Saccharomyces)、コリネバクテリウム属(Corynebacterium)、ストレプトマイセス属(Streptomyces)、サルモネラ属(Salmonella)、アスペルギルス属(Aspergillus)、グルコノバクター属(Gluconobacter)、マイコバクテリウム属(Mycobacterium)、放線菌類(Actinomycetes)、カウロバクター属(Caulobacter)、ピキア属(Pichia)、コリネバクテリウム・グルタミカム(Corynebacterium glutamicum)、サッカロミセス・セレビシエ(Saccharomyces cerevisiae)、クロストリジウム・ボツリヌム(Clostridium botulinum)、フラボバクテリウム・ヘパリナム(Flavobacterium heparinum)、ラクトコッカス・ラクティス(Lactococcus lactis)、メチロバクテリウム・エキストロクエンス(Methylobacterium extorquens)、シュードアルテロモナス・ハロプランクティス(Pseudoalteromonas haloplanktis)、ラルストニア・ユートロファ(Ralstonia eutropha)、ニューロスポラ・クラッサ(Neurospora crassa)、アルクスラ・アデニニボランス(Arxula adeninivorans)、ハンセヌラ・ポリモルファ(Hansenula polymorpha)、クルイウェロマイセス・ラクティス(Kluyveromyces lactis)、ジゴサッカロマイベス・バイリー(Zygosaccharomyves bailii)、シュードモナス・フルオレッセンス(Pseudomonas fluorescens)、バチルス・サブティリス(Bacillus subtilis)及びバチルス・メガテリウム(Bacillus megaterium)で構成されている群から選択される。好ましい実施形態では、微生物はバチルス属又はシュードモナス属で構成されている群から選択される。より好ましい実施形態では、前記微生物はバチルス・サブティリス又はシュードモナス・フルオレッセンスである。
本明細書中で使用されるように、「食餌療法組成物」はヒトの食用に適している組成物である。食餌療法組成物は主にタンパク質を含むことができる。本発明の食餌療法組成物は、本発明の組換え食餌療法タンパク質又はその食餌療法として十分な部分を含み、かつ総フェニルアラニン量が少ない。
フェニルアラニンを含まない栄養タンパク質について必要な基準を満たす潜在的なタンパク質候補を同定するために、自己設計した検索アルゴリズムを使用した。様々な属又は種に由来するタンパク質配列を、CLC Main Workbench 6.6.1のインポート機能を使用してUniProtデータベース(http://www.uniprot.org)から入手した。
配列番号7に示すようなヌクレオチド配列を有する合成遺伝子GSP105を、バチルス・サブティリス発現ベクターpHT43(モビテック(MoBiTec)、ドイツ連邦共和国ゲッチンゲン)に挿入して培地中への組換えタンパク質の分泌を可能とし、そしてプロテアーゼが欠損したB.サブティリス菌株WB800N(モビテック)に製造業者の説明書に従って導入した。
研究計画:
6匹の雄の成体のホモ接合体のPKUマウス(Pahenu2/2;シェドロフスキー(Shedlovsky)ら、ジェネティクス(Genetics)、1993年、第134巻、p.1205;http://www.pahdb.mcgill.ca/?Topic=Information&Section=Mouse&Page=1)を、それぞれマウス2匹の3群に分けた。同じ群に属する動物にケージを共用させた。これらの群には表4に記されるような治療食を与えた。治療食の間の主な違いは、表5に示されるように、タンパク質成分及びPhe含有量であった。給餌研究より以前は、PKUマウスに標準的なマウス用飼料を与えた。給餌研究は28日間に及び、その間、動物は食物及び水を自由摂取とした。
第0、1、7、14、21及び28日目において、動物を4時間絶食させた後に該動物の尾静脈から5〜10μlの血液を試料採取した。血漿中のPhe及びチロシンの含有量を、MS/MS分析によって測定した。
第14、21及び28日目には、マウスの体重計測のみを行った。第28日目に、全ての動物をCO2で安楽死させた。各動物の肝臓、腎臓、脳及び心臓を、さらなる分析のために摘出して液体窒素中で凍結させた。
体重
標準的なマウス用飼料を与えると、原則として体重が維持された(図1、実線と正方形)。Phe非含有GSP105タンパク質治療食を与えられると、PKUマウスは体重が増加した(図1、点線と円)一方、Phe非含有アミノ酸治療食を与えられたマウスは軽微な体重減少を示した(図1、破線と三角形)。群の大きさが小さく統計分析はできなかったが、観察された傾向は、体重維持及び体重増加のうち少なくともいずれか一方に適したタンパク質成分としてGSP105を支持している。観察された体重増加は、これがカゼインより高い生物学的栄養価を備えた食餌療法タンパク質であるという事実に起因するかもしれない。
標準的なマウス用飼料のPKUマウスは、高い血中平均Pheレベルを保持した(図2、実線と正方形)。Phe非含有アミノ酸治療食は、血中平均Pheレベルの激的な低下をもたらした(1リットル当たり<360マイクロモル、PKU治療が目指す生理的範囲)(図2、破線と三角形)。Phe非含有GSP105タンパク質治療食の動物の平均血中Pheレベルも明白に低下し、28日後に1リットル当たり<360マイクロモルに近づいた(図2、点線と円)。これらの結果は、開示された組換え食餌療法タンパク質が食餌療法によるPKU管理に適していることを示している。
Phe非含有アミノ酸治療食がPKUマウスの血漿中の最も低いPhe/Tyr比率をもたらし(図4、破線と三角形)、続いてPhe非含有GSP105タンパク質治療食であった(図4、点線と円)。標準的なマウス用飼料マウスのPKUマウスは参照として実線と正方形とで図4に示されている。Phe非含有GSP105タンパク質治療食についてのPhe/Tyr比率は、精製された組換え食餌療法タンパク質GSP105からのPhe混入物の量を低減すること、及びPhe非含有アミノ酸治療食で使用されるような結晶状のチロシンの補足又はチロシン含有デザイナーテールの添加、のうち少なくともいずれか一方により、改善されることもありうる。
方法:
マウス脳組織の調製
実施例3の動物の脳を使用した。凍結されたマウスの全脳を氷上で融解して、50mm Tris−HCl(pH7.5)、0.1m KCl、1mm EDTA、1mm ジチオトレイトール、0.2mm フェニルメチルスルホニルフルオリド、1μmロイペプチン及び1μmペプスタチンを含有する均質化バッファー(組織1mgあたり10μl)の中で溶解し、そしてキアゲン(Quiagen)のTissueLyser IIを使用して4℃で均質化した。13,000g及び4℃で30分間の遠心分離の後、上清を−80℃で凍結させておいた。
均質化した組織中のタンパク濃度は、較正物質としてγ−グロブリンを使用して、ブラッドフォード(Bradford)が述べた分光光度法によって測定した。
試料はフェノメネクス(Phenomenex)のEZ:faast(商標)キットの手引書に従って調製したが、ただし次の改変を加えた:アミノ酸の抽出及び誘導体化に先立ち、(50mmol/LのHCl中に)100μmol/LのPhe−d5及び20μmol/LのTyr−d4を含有する各内部標準溶液20μLを、40μLの試料溶解産物に加えた。キットの試薬を使用して、アミノ酸のアミン部分にギ酸プロピル及びカルボキシル端にプロピル基をそれぞれ付加するクロロギ酸プロピルを用いてアミノ酸を誘導体化する。Tyrの水酸基もギ酸プロピル基の付加によって誘導体化される。
アミノ酸のRP(逆相)−HPLC分離については、250×2mmのC18カラム(フェノメネクスのEZ:faast(商標))を使用した。誘導体化したアミノ酸を、次のプログラム:(i)均一溶媒流の75%溶媒Bを6分間;(ii)75%から95%への溶媒B(v/v)の直線濃度勾配、9分間;(iii)95%から100%への溶媒Bの直線濃度勾配、0.1分間;(iv)均一溶媒流の100%溶媒Bを3分間;(v)100%から75%への溶媒Bの直線濃度勾配、0.1分間;(vi)均一溶媒流の75%溶媒Bを2分間、を使用して分離した。溶媒A及びBはそれぞれ、H2O中に10mmol/Lのギ酸アンモニウム溶液及びメタノール中に10nmol/Lのギ酸アンモニウム溶液であった。流量を150μL/分とし、注入体積を10μLとした。パーキンエルマー(PerkinElmer)のSCIEX API 2000 LC−ESI−MSMSシステムにパーキンエルマーのシリーズ200オートサンプラー及びパーキンエルマーのシリーズ200マイクロポンプ2台を装備したものを、LC−ESI−MSMS分析に使用した。アミノ酸は、多重反応モード(MRM)陽イオンモードを使用して、次のトランジション:294→206(Phe)、299→211(Phe−d5)、302→214(Phe−d8)、396→308(Tyr)及び400→312(Tyr−d4)を伴って得られた。滞留時間は500ミリ秒であった。質量スペクトルを6〜20分の時間範囲で得た。
脳内Pheレベルの低減
図5は、野生型(WT)マウス、及び標準的なマウス用飼料、Phe非含有GSP105タンパク質治療食又はPhe非含有アミノ酸治療食で治療されたPKUマウスの脳内におけるPhe及びTyrの平均濃度を示す。
図6は、WTマウス、及び標準的なマウス用飼料、Phe非含有GSP105タンパク質治療食又はPhe非含有アミノ酸治療食で治療されたPKUマウスの脳内の平均Phe/Tyr比率を示している。
Claims (15)
- 配列番号2と少なくとも90%同一であるポリペプチド配列を含む組換え食餌療法タンパク質であって、前記タンパク質はフェニルアラニンを含んでいない、組換え食餌療法タンパク質。
- 前記ポリペプチド配列は、配列番号2と少なくとも95%、好ましくは97%、より好ましくは98%同一である、請求項1に記載の組換え食餌療法タンパク質。
- タンパク質は1以上の追加のタンパク質配列をさらに含み、追加のタンパク質配列は精製タグ又はラベルである、請求項1又は2に記載の組換え食餌療法タンパク質。
- 追加のタンパク質配列は、アミノ酸配列である配列番号3を含むポリペプチドタグである、請求項3に記載の組換え食餌療法タンパク質。
- 請求項1〜4のいずれか1項に記載の組換え食餌療法タンパク質をコードする核酸配列を含むベクター。
- 請求項5に記載のベクターを含む組換え微生物。
- 微生物は、エシェリキア属(Escherichia)、クレブシェラ属(Klebsiella)、シュードモナス属(Pseudomonas)、キサントモナス属(Xanthomonas)、バチルス属(Bacillus)、スタフィロコッカス属(Staphylococcus)、サッカロミセス属(Saccharomyces)、コリネバクテリウム属(Corynebacterium)、ストレプトマイセス属(Streptomyces)、サルモネラ属(Salmonella)、アスペルギルス属(Aspergillus)、グルコノバクター属(Gluconobacter)、マイコバクテリウム属(Mycobacterium)、放線菌類(Actinomycetes)、カウロバクター属(Caulobacter)、ピキア属(Pichia)、コリネバクテリウム・グルタミカム(Corynebacterium glutamicum)、サッカロミセス・セレビシエ(Saccharomyces cerevisiae)、クロストリジウム・ボツリヌム(Clostridium botulinum)、フラボバクテリウム・ヘパリナム(Flavobacterium heparinum)、ラクトコッカス・ラクティス(Lactococcus lactis)、メチロバクテリウム・エキストロクエンス(Methylobacterium extorquens)、シュードアルテロモナス・ハロプランクティス(Pseudoalteromonas haloplanktis)、ラルストニア・ユートロファ(Ralstonia eutropha)、ニューロスポラ・クラッサ(Neurospora crassa)、アルクスラ・アデニニボランス(Arxula adeninivorans)、ハンセヌラ・ポリモルファ(Hansenula polymorpha)、クルイウェロマイセス・ラクティス(Kluyveromyces lactis)、ジゴサッカロマイベス・バイリー(Zygosaccharomyves bailii)、シュードモナス・フルオレッセンス(Pseudomonas fluorescens)、バチルス・サブティリス(Bacillus subtilis)及びバチルス・メガテリウム(Bacillus megaterium)で構成されている群から選択される、請求項6に記載の組換え微生物。
- 前記微生物はバチルス属細菌又はシュードモナス属細菌である、請求項7に記載の組換え微生物。
- 前記微生物はバチルス・サブティリス又はシュードモナス・フルオレッセンスである、請求項8に記載の組換え微生物。
- 請求項1〜4のいずれか1項に記載の組換え食餌療法タンパク質を生産する方法であって、前記方法は、請求項6〜9のいずれか1項に記載の組換え微生物を、組換え微生物による食餌療法タンパク質の生産に適した条件下で培養することを含む、方法。
- 請求項1〜4のいずれか1項に記載の組換え食餌療法タンパク質及び任意選択でさらなる添加剤を含む食餌療法組成物。
- タンパク質100gあたり0.45g以下のフェニルアラニンしか含んでいない請求項1〜4のいずれか1項に記載の食餌療法タンパク質、又は100gの総タンパク質あたり0.1g以下のフェニルアラニンしか含んでいない請求項11に記載の食餌療法組成物。
- 医薬及び特殊な医療目的のための食品のうち少なくともいずれか一方として使用するための、請求項1〜4のいずれか1項に記載の食餌療法タンパク質又は請求項11に記載の食餌療法タンパク質組成物。
- 体内へのフェニルアラニンの蓄積を特徴とする障害の治療に使用するための、請求項1〜4のいずれか1項に記載の食餌療法タンパク質又は請求項11に記載の食餌療法タンパク質組成物。
- 前記障害は高フェニルアラニン血症、好ましくはフェニルケトン尿症である、請求項14に記載の使用のための請求項1〜4のいずれか1項に記載の食餌療法タンパク質又は請求項11に記載の食餌療法タンパク質組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16186895.5A EP3290436B1 (en) | 2016-09-01 | 2016-09-01 | Phenylalanine-free protein for the treatment of pku |
EP16186895.5 | 2016-09-01 | ||
PCT/EP2017/071814 WO2018041920A1 (en) | 2016-09-01 | 2017-08-30 | Phenylalanine-free protein for the treatment of pku |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019533988A JP2019533988A (ja) | 2019-11-28 |
JP2019533988A5 JP2019533988A5 (ja) | 2020-08-20 |
JP6954676B2 true JP6954676B2 (ja) | 2021-10-27 |
Family
ID=56883591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019512755A Active JP6954676B2 (ja) | 2016-09-01 | 2017-08-30 | Pku治療のためのフェニルアラニン非含有タンパク質 |
Country Status (27)
Country | Link |
---|---|
US (1) | US10640538B2 (ja) |
EP (1) | EP3290436B1 (ja) |
JP (1) | JP6954676B2 (ja) |
CN (1) | CN109661401B (ja) |
AU (1) | AU2017317652B2 (ja) |
BR (1) | BR112019004270A2 (ja) |
CA (1) | CA3033271C (ja) |
CY (1) | CY1121886T1 (ja) |
DK (1) | DK3290436T3 (ja) |
ES (1) | ES2742175T3 (ja) |
HR (1) | HRP20191406T1 (ja) |
HU (1) | HUE044665T2 (ja) |
IL (1) | IL265015B1 (ja) |
LT (1) | LT3290436T (ja) |
MA (1) | MA43352B1 (ja) |
MD (1) | MD3290436T2 (ja) |
ME (1) | ME03510B (ja) |
MX (1) | MX2019002422A (ja) |
NZ (1) | NZ750498A (ja) |
PL (1) | PL3290436T3 (ja) |
PT (1) | PT3290436T (ja) |
RU (1) | RU2764796C2 (ja) |
SA (1) | SA519401175B1 (ja) |
SI (1) | SI3290436T1 (ja) |
UA (1) | UA124630C2 (ja) |
WO (1) | WO2018041920A1 (ja) |
ZA (1) | ZA201901505B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110747218A (zh) * | 2019-09-27 | 2020-02-04 | 深圳市诺维健生物技术有限责任公司 | 一种特殊膳食蛋白质的生产方法与应用 |
CN113214363B (zh) * | 2019-09-27 | 2022-12-06 | 湖北康肽药业有限公司 | 一组特殊膳食蛋白质 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04126051A (ja) * | 1990-09-18 | 1992-04-27 | Snow Brand Milk Prod Co Ltd | フェニルケトン尿症患者用栄養調製物 |
GB9310472D0 (en) | 1993-05-20 | 1993-07-07 | Univ Warwick | Phenylalanine-free protein and dna coding thereof |
GB9314802D0 (en) * | 1993-07-16 | 1993-08-25 | Pharmaceutical Proteins Ltd | Modified proteins |
WO1996017064A1 (en) | 1994-12-02 | 1996-06-06 | Indiana University Foundation | Phenylalanine free proteins |
EP1092769B1 (de) * | 1999-10-15 | 2008-10-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Polypeptid-Tag's für den Nachweis und die Aufreinigung von Polypeptiden |
KR20030085112A (ko) * | 2000-12-07 | 2003-11-03 | 디에스엠 아이피 어셋츠 비.브이. | 카르복시 말단 프롤린 잔기를 갖는 펩티드가 풍부한단백질 가수분해물 |
US9034402B2 (en) * | 2007-04-16 | 2015-05-19 | Solae, Llc | Protein hydrolysate compositions having improved sensory characteristics and physical properties |
AU2008245696B2 (en) | 2007-04-27 | 2013-11-07 | Pelican Technology Holdings, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US20100316623A1 (en) * | 2009-04-23 | 2010-12-16 | Andrew Turner | Phenylalanine hydroxylase fusion protein and methods for treating phenylketonuria |
WO2013133691A1 (en) * | 2012-03-09 | 2013-09-12 | N.V. Nutricia | Liquid nutritional composition comprising free amino acids |
MX2014011614A (es) | 2012-03-26 | 2015-04-08 | Pronutria Inc | Fragmentos y proteinas nutritivas con fenilalanina baja o nula y metodos. |
CN104936466A (zh) | 2012-11-20 | 2015-09-23 | 普罗努塔利亚公司 | 工程化的分泌蛋白质和方法 |
WO2016046234A2 (en) | 2014-09-22 | 2016-03-31 | Nexttobe Ab | Recombinant phe-free proteins for use in the treatment of phenylketonuria |
-
2016
- 2016-09-01 ES ES16186895T patent/ES2742175T3/es active Active
- 2016-09-01 PT PT16186895T patent/PT3290436T/pt unknown
- 2016-09-01 MA MA43352A patent/MA43352B1/fr unknown
- 2016-09-01 MD MDE20180783 patent/MD3290436T2/ro unknown
- 2016-09-01 SI SI201630331T patent/SI3290436T1/sl unknown
- 2016-09-01 HU HUE16186895 patent/HUE044665T2/hu unknown
- 2016-09-01 PL PL16186895T patent/PL3290436T3/pl unknown
- 2016-09-01 EP EP16186895.5A patent/EP3290436B1/en active Active
- 2016-09-01 DK DK16186895.5T patent/DK3290436T3/da active
- 2016-09-01 ME MEP-2019-208A patent/ME03510B/me unknown
- 2016-09-01 LT LTEP16186895.5T patent/LT3290436T/lt unknown
-
2017
- 2017-08-30 UA UAA201903097A patent/UA124630C2/uk unknown
- 2017-08-30 AU AU2017317652A patent/AU2017317652B2/en active Active
- 2017-08-30 RU RU2019109142A patent/RU2764796C2/ru active
- 2017-08-30 CN CN201780053903.8A patent/CN109661401B/zh active Active
- 2017-08-30 US US16/329,027 patent/US10640538B2/en active Active
- 2017-08-30 NZ NZ750498A patent/NZ750498A/en unknown
- 2017-08-30 CA CA3033271A patent/CA3033271C/en active Active
- 2017-08-30 JP JP2019512755A patent/JP6954676B2/ja active Active
- 2017-08-30 WO PCT/EP2017/071814 patent/WO2018041920A1/en active Application Filing
- 2017-08-30 IL IL265015A patent/IL265015B1/en unknown
- 2017-08-30 BR BR112019004270A patent/BR112019004270A2/pt unknown
- 2017-08-30 MX MX2019002422A patent/MX2019002422A/es unknown
-
2019
- 2019-02-24 SA SA519401175A patent/SA519401175B1/ar unknown
- 2019-03-11 ZA ZA2019/01505A patent/ZA201901505B/en unknown
- 2019-08-02 HR HRP20191406 patent/HRP20191406T1/hr unknown
- 2019-08-08 CY CY20191100853T patent/CY1121886T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7303238B2 (ja) | 荷電栄養タンパク質および方法 | |
JP7122141B2 (ja) | 栄養断片、タンパク質、および方法 | |
JP2015518470A (ja) | 栄養タンパク質および方法 | |
KR20210111781A (ko) | 크립토코커스 테레스트리스 유래의 베타-갈락토시다제를 이용한 gos-제제의 제조 방법, 이에 의해서 수득 가능한 gos 제제 및 이의 용도 | |
JP6954676B2 (ja) | Pku治療のためのフェニルアラニン非含有タンパク質 | |
WO2014090261A1 (en) | Mixture of fucosylate lactoses | |
JP2524551B2 (ja) | グルタミン含量の高いペプチド組成物、その製造方法及び経腸栄養剤 | |
JP2014195433A (ja) | D−アミノ酸の製造方法 | |
WO2021059894A1 (ja) | 組成物並びに該組成物含有する飲食品組成物および調製乳 | |
JP3789564B2 (ja) | ポリアミンの調製方法 | |
JP5002442B2 (ja) | 脂質吸収促進剤 | |
JP3448344B2 (ja) | ペプチド組成物 | |
CA2012278C (en) | Mutant of microbacterium, a strain 851r, and a process for producing 851r nutrient solution by application of the strain | |
Hernández-Almanza et al. | Microbial production of bioactive pigments, oligosaccharides, and peptides | |
JP3850740B2 (ja) | 乳由来の非タンパク態窒素化合物、l−カルニチンの濃縮方法、l−カルニチン濃縮物及びその利用 | |
TWI466896B (zh) | 分離自一鮪魚蒸煮液的水解產物的胜肽以及該水解產物與該等胜肽的應用 | |
JP2018123070A (ja) | 血管内皮機能改善剤 | |
JPH0930978A (ja) | タイトジャンクション形成促進剤 | |
JP3789146B2 (ja) | オリゴ糖含有栄養組成物 | |
RU2366263C2 (ru) | Бульон с профилактическими свойствами, содержащий белковый гидролизат, и способ получения этого белкового гидролизата | |
Gonzalez et al. | Advances in Milk Fractionation for Value Addition | |
JP2007022966A (ja) | 細胞死抑制物質とその利用法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200708 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200708 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210804 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210901 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210922 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6954676 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |